Fig. 3

Changes in FLT uptake from baseline to the day of early evaluation. SUVmax decreased significantly in the group of responders, whereas the group of non-responders did not show a significant decrease in FLT uptake. The patient with progressive disease is illustrated with a black line in the group of non-responders